Business Wire

Thousands Convene in Houston to Learn About the Latest In Automation Technology While Helping to Support Area Recovery

Del

Thousands of industrial professionals are convening in Houston for the Automation Fair event to learn more about the latest advanced manufacturing technologies shaping the industry, and the automation tools that can help them be more globally competitive and productive. Hosted by Rockwell Automation and its PartnerNetwork members, the Automation Fair event is the premier industry experience uniquely designed to help manufacturers and OEMs optimize their automation investments to achieve their business goals.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171115006551/en/

Blake Moret, president and CEO, Rockwell Automation, shares his vision and insights on how companies ...

Blake Moret, president and CEO, Rockwell Automation, shares his vision and insights on how companies are realizing value from digital transformation and advanced technologies, in a presentation at the Automation Perspectives global media forum held on Nov. 14. (Photo: Business Wire)

“This week is about showcasing technologies and information that help make industrial companies and their people more productive. We are also taking the opportunity to show our support for the people of Houston and surrounding communities as they continue to rebuild and recover from the recent hurricanes,” said Blake Moret, president and CEO, Rockwell Automation.

At the event, attendees are seeing a variety of technologies that help support digital transformation – using production data to improve business outcomes – and best practices for monitoring and managing operations to increase integration and collaboration across the enterprise. To this end, Rockwell Automation has again expanded its analytics offering, with a new platform that pulls data from virtually any source in the enterprise, and delivers analytics in intuitive dashboards, helping users to rapidly resolve issues and drive tangible business outcomes across The Connected Enterprise.

Hundreds of process automation professionals arrived early in Houston to attend the annual Process Solutions Users Group (PSUG), held on Nov. 13 and 14. The event featured over 25 technical sessions, 10 hands-on labs and more than 25 presentations by Rockwell Automation customers, including an open forum panel of industry experts.

On Nov. 14, global media and industry analysts attended the half-day media forum, Automation Perspectives. At this event, executive leadership and industry experts shared their vision and thought-leadership on ways companies are realizing value from digital transformation across industries, and the technologies being used to achieve this. Industry leaders also shared their strategies for addressing the manufacturing skills shortage, with a new program developed jointly by Rockwell Automation and ManpowerGroup that taps into the talents and skills of U.S. military veterans to help solve this critical challenge.

In conjunction with the Automation Fair event, employees, partners and customers of Rockwell Automation are joining forces with United Way to help pack over 8,000 Thanksgiving dinner kits, part of the company’s ongoing effort to support hurricane recovery efforts, and build on its commitment to Houston. Together, the two organizations are helping to distribute dinner kits to residents immediately following the conclusion of the Automation Fair event through various United Way affiliate agencies and partners.

The 2017 Automation Fair event features more than 140 exhibits showcasing the latest innovations in automation. It also includes nine industry forums, 19 hands-on labs and 93 technical sessions designed to expand attendee knowledge and use of the latest control, power and advanced manufacturing and enterprise information technologies.

For images, resources and information on product and related announcements at the event, please visit the Automation Fair online pressroom.

About the Rockwell Automation PartnerNetwork Program

The Rockwell Automation PartnerNetwork program offers global manufacturers access to a collaborative network of companies mutually focused on developing, implementing and supporting best-in-breed solutions to achieve plantwide optimization, improve machine performance and meet sustainability objectives.

About Rockwell Automation

Rockwell Automation Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and information, makes its customers more productive and the world more sustainable. Headquartered in Milwaukee, Wis., Rockwell Automation employs approximately 22,000 people serving customers in more than 80 countries.

Automation Fair, LISTEN.THINK.SOLVE. and PartnerNetwork are trademarks of Rockwell Automation Inc.

Contact information

Beatrice Zvosec
Padilla
612.455.1914
beatrice.zvosec@padillaco.com
or
Kristen Crump
Rockwell Automation
414.382.0068
klcrump@ra.rockwell.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45Pressemelding

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10Pressemelding

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an